Health Care & Life Sciences » Biotechnology | Hemispherx Biopharma Inc.

Hemispherx Biopharma Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
16,225.00
17,450.00
15,230.00
7,502.00
8,259.00
Depreciation, Depletion & Amortization
691.00
1,142.00
975.00
1,169.00
1,004.00
Other Funds
1,524.00
457.00
774.00
1,076.00
1,819.00
Funds from Operations
14,010.00
15,851.00
13,481.00
7,409.00
9,074.00
Changes in Working Capital
2,820.00
1,933.00
2,572.00
29.00
1,133.00
Net Operating Cash Flow
16,830.00
13,918.00
16,053.00
7,380.00
7,941.00
Capital Expenditures
1,140.00
762.00
490.00
454.00
69.00
Purchase/Sale of Investments
23,479.00
3,248.00
6,842.00
3,370.00
2,799.00
Net Investing Cash Flow
22,268.00
2,488.00
6,352.00
2,916.00
2,730.00
Issuance/Reduction of Debt, Net
7,096.00
34.00
21.00
13.00
1,798.00
Net Financing Cash Flow
6,847.00
12,783.00
9,660.00
4,757.00
4,215.00
Net Change in Cash
1,409.00
1,353.00
41.00
293.00
996.00
Free Cash Flow
17,728.00
14,422.00
16,293.00
7,540.00
7,961.00
Other Sources
-
2.00
-
-
-
Change in Capital Stock
249.00
12,817.00
9,681.00
4,744.00
2,417.00
Other Uses
71.00
-
-
-
-

About Hemispherx Biopharma

View Profile
Address
2117 South West Highway 484
Ocala Florida 32801
United States
Employees -
Website http://www.hemispherx.net
Updated 09/14/2018
Hemispherx Biopharma, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.